FDA approves phase III clinical trial evaluating siltuximab plus standard of care for patients with COVID-19 associated acute respiratory distress syndrome (ARDS)

Siltuximab is a monoclonal antibody that directly neutralises interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. RCT will aim to enrol ~400 patients with viral ARDS and elevated serum levels of IL-6.